Renub Research

Hepatitis C Market & Forecast, HCV Drugs Clinical Trials, Hepatitis C Pipeline Drugs Sales & Forecast - Worldwide

Press Release   •   Sep 16, 2014 03:17 EDT

 •  The worldwide hepatitis C (HCV) market is expected to grow with double digit for the period of 2013 - 2018. •  Incivek sales are expected to fall down by the year 2016. •  Pegintron faces patent expirations in 2015, 2018 and 2020.  •  Abbott has various drugs currently being tested in clinical trials namely Abbott's ABT-450/r, ABT-267, ABT-072/333. •  Bristol-Myers Squibb has Daclatasvir (BMS-790052), Asunaprevir (BMS-650032) and PEG-IFN-lambda currently being studied in clinical trials. •  Roche has two drugs namely Mericitabine (RG-7128) and Danoprevir/r (RG-7227) for investigation currently in clinical trials for HCV.

Renub Research study titled “Hepatitis C Market & Forecast, HCV Drugs Clinical Trials, Hepatitis C Pipeline Drugs Sales & Forecast - Worldwide” provides a comprehensive assessment of the fast-evolving, high-growth of Hepatitis sector. This 164 page report with 25 Figures and 2 Tables studies the Hepatitis C Drug Market Landscape. This report contains 7 chapters. A. Hepatitis C Drugs Market & Forecast (Chapter 2) B. Hepatitis C Approved Drugs Sales & Forecast (Chapter 3) C. Hepatitis C Deals & Acquisitions (Chapter 4) D. Hepatitis C – Pipeline Drugs Clinical Trials (Drugs in Phase III) (Chapter 5) E. Hepatitis C – Pipeline Drugs Clinical Trials (Drugs in Phase II) (Chapter 6) F. Hepatitis C - Pipeline Drugs Sales Forecast (Chapter 7) Hepatitis C – Approved Drugs sales & Forecast Analysis (To 2016) (Chapter No. 3)  1. Pegasys 2. Pegintron 3. Incivek4. Victrelis Hepatitis C – Pipeline Drugs Clinical Trials (Drugs in Phase III) (Chapter No. 5)  1. Simeprevir (TMC 435) (Company: Janssen Pharmaceutical)2. Faldaprevir (BI 201335) (Company: Boerhinger Ingelheim)3. Asunaprevir (BMS-650032) (Company: Bristol-Myers Squibb)4. PEG-Interferon Lambda (Company: Bristol-Myers Squibb)5. Sofosbuvir (PSI-7977 or GS-7977) (Company: Gilead Sciences)6. Daclatasvir (BMS-790052) (Company: Bristol-Myers Squibb)7. BI-207127 (Company: Boerhinger Ingelheim)8. ABT-450/r (Ritonavir) (Company: Abbott Laboratories)9. ABT-267 (Company: Abbott Laboratories)10. ABT-072/333 (Company: Abbott Laboratories)11. Alisporivir (Company: Novartis) Hepatitis C – Pipeline Drugs Clinical Trials (Drugs in Phase II) (Chapter No. 6)  1. Mericitabine (RG-7128) (Company: Roche)2. Danoprevir/r (Ritonavir) (RG7227) (Company: Roche)3. GS-9256 (Company: Gilead Sciences)4. GS-9451 (Company: Gilead Sciences)5. MK-5172 (Company: Merck)6. Sovaprevir (ACH-1625) (Company: Achillion)7. IDX-320 (Company: Idenix)8. MK-8742 (Company: Merck)9. ACH-3102 (Company: Achillion Pharmaceuticals, Inc)10. IDX-719 (Company: Idenix)11. PPI-668 (Company: Presidio Pharmaceuticals)12. Setrobuvir (ANA-598) (Company: Roche)13. VX-222 (Company: Vertex Pharmaceuticals)14. GS-9669 (Company: Gilead Sciences)15. GS-9190 (Tegobuvir) (Company: Gilead Sciences)16. BMS-791325 (Company: Bristol-Myers Squibb) Hepatitis C - Pipeline Drugs Sales Forecast (Chapter 7) 1. Simeprevir (TMC 435) 2. Faldaprevir (BI 201335) (Boerhinger Ingelheim) 3. Asunaprevir (BMS-650032) 4. Sofosbuvir (PSI-7977 or GS-7977) 5. Daclatasvir (BMS-790052) 6. ABT-450/r (Ritonavir) 7. ABT-072/333 8. Alisporivir 9. Mericitabine (RG-7128)10. Danoprevir (RG7227) 11. GS-925612. Setrobuvir (ANA-598) 13. VX-222 14. GS-9190 (Tegobuvir)15. BMS-791325   Data Sources This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by Renub Research team of industry experts. Primary sources include industry surveys and telephone interviews with industry experts.  Secondary sources information and data has been collected from various printable and non-printable sources like search engines, News websites, Government Websites, Trade Journals, White papers, Government Agencies, Magazines, Newspapers, Trade associations, Books, Industry Portals, Industry Associations and access to more than 500 paid databases. 

Contact Us
Rajat GuptaSr. ManagerSales & Marketing DivRenub ResearchEmail: Phone:  +1-678-302-0700 (USA), +91-120-421-9822, +91-120-254-5750 (India)Web: